News & Videos - GT BIOPHARMA INC. GTBP

GT Biopharma's Chairman and Chief Executive Officer Raymond W Urbanski, M.D., Ph.D Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration PR Newswire LOS ANGELES, August 30, 2018 LOS ANGELES , August 30, 2018 /PRNewswire/ -- GT Biopharma Inc. (GTBP) (Euronext Paris: GTBP.PA) is an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary NK-engager and Bispecific Antibody Drug Conjugate platforms. Monday was a...

GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration PR Newswire LOS ANGELES, August 29, 2018 LOS ANGELES , August 29, 2018 /PRNewswire/ -- GT Biopharma Inc. (GTBP) and (Euronext Paris: GTBP.PA) is an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary NK-engager and Bispecific Antibody Drug Conjugate platforms. Monday was a monumental and reassuring day for...

GT Biopharma Announces the Appointment of David Cardino, CPA, MBA as Vice President of Finance PR Newswire LOS ANGELES, August 24, 2018 LOS ANGELES , August 24, 2018 /PRNewswire/ -- Biopharma Inc. (GTBP) and (Euronext Paris: GTBP.PA), an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary platforms, today announced the appointment of David Cardino , CPA, MBA as Vice President of Finance effective August 20, 2018 . "Dave brings extensive...

GT Biopharma Announces GTBP CEO, Dr. Raymond Urbanski, to Make Presentation at the 2018 Wedbush PacGrow Healthcare Conference PR Newswire LOS ANGELES, August 14, 2018 LOS ANGELES , August 14, 2018 /PRNewswire/ -- GT Biopharma Inc. (OTCQB: GTBP) and (Euronext Paris: GTBP.PA), an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary platforms, announced today the Chief Executive Officer, Dr. Raymond W. Urbanski , will present at the Wedbush...

GT Biopharma Announces the Addition of Dr. John N. Bonfiglio to its Board of Directors PR Newswire LOS ANGELES, July 25, 2018 LOS ANGELES , July 25, 2018 /PRNewswire/ -- GT Biopharma Inc. (OTCQB: GTBP) (Euronext Paris: GTBP.PA), an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary platforms, today announced the addition of Dr. John N. Bonfiglio to GT Biopharma's Board of Directors on July 5, 2018 . "John is a welcome addition to our already...

GT Biopharma Inc. Announces Agreement with a Major Pharmaceutical Company to Study its Drug Candidate OXS-1550 in Combination With a Multi-Billion Dollar Oncology Drug PR Newswire LOS ANGELES, July 19, 2018 LOS ANGELES , July 19, 2018 /PRNewswire/ -- GT Biopharma Inc. (GTBP) and (Euronext Paris: GTBP.PA) announced today a Material Transfer Agreement (MTA) between a Major Pharmaceutical Company and Dr. Daniel Vallera , Director, Section of Molecular Cancer Therapeutics at the Masonic Cancer...

GT Biopharma Announces Voluntary Lock-Up Agreements With Insiders Covering Over 52% of Outstanding Shares PR Newswire LOS ANGELES, June 5, 2018 LOS ANGELES , June 5, 2018 /PRNewswire/ -- GT Biopharma Inc. (OTCQB: GTBP) (Euronext Paris: GTBP.PA) or the "Company", an immuno-oncology biotechnology company focused on innovative treatments based on the Company's proprietary platforms, announces that the officers, non-independent directors of the Company and a significant founding shareholder of GT...

Gt Biopharma Announces Dr. Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company PR Newswire LOS ANGELES, May 14, 2018 LOS ANGELES , May 14, 2018 /PRNewswire/ -- GT Biopharma Inc. (OTCQB: GTBP)(Euronext Paris GTBP.PA) today announced the promotion of Dr. Raymond W Urbanski MD, PhD to the position of President and Chief Medical Officer effective immediately. Dr. Urbanski will report to Shawn Cross , the Company's Chief Executive Officer. "I am pleased to announce the...

Seasoned Financial Executive Federica O'Brien Joins GT Biopharma's Board of Directors PR Newswire LOS ANGELES, April 26, 2018 LOS ANGELES , April 26, 2018 /PRNewswire/ -- GT Biopharma Inc. (OTCQB: GTBP and Euronext Paris "GTBP.PA"), an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary platforms, today announced the addition of Federica O'Brien , CPA to GT Biopharma's board of directors effective immediately. Ms. O'Brien is expected to chair...

Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors PR Newswire LOS ANGELES, April 24, 2018 LOS ANGELES , April 24, 2018 /PRNewswire/ -- GT Biopharma Inc. (OTCQB: GTBP and Euronext Paris "GTBP.PA") today announced that Dr. Peter Kiener will join GT Biopharma's Board of Directors, effective immediately. Dr. Peter Kiener has substantial experience in both biologics and immunotherapy, and was most recently the Chief Scientific Officer at Sucampo, which...

WASHINGTON, D.C. / ACCESSWIRE / March 29, 2018 / GT Biopharma Inc. (OTCQB: GTBP) (Euronext Paris: GTBP.PA) (the "Company") wishes to make the following statements regarding recent market activity in its common stock traded on the OTCQB marketplace: The Company became aware of certain promotional activity on its securities on March 27, 2018, upon receipt of correspondence from OTC Markets specifically related to an article posted on biotechstocks.com, which article was originally published on...

GT Biopharma Inc. Announces >50% Enrollment in Proof-Of-Concept Clinical Trial For Its Novel Treatment For Motion Sickness PR Newswire WASHINGTON, March 29, 2018 WASHINGTON , March 29, 2018 /PRNewswire/ -- GT Biopharma Inc. (OTCQB: GTBP) (Euronext Paris: GTBP.PA) announced today that the Proof-of-Concept clinical trial with GTP-011, a novel treatment for the symptoms of motion sickness, that was initiated in late February 2018 is more than 50% enrolled. The study is a single-blind,...

GT Biopharma Announces Dr. Jeffrey Miller, Renowned NK Cell Cancer Specialist, Will Present at Cell Therapy Symposia TriKE and TetraKE Platforms to be Highlighted PR Newswire LOS ANGELES, February 13, 2018 LOS ANGELES , February 13, 2018 /PRNewswire/ -- GT Biopharma Inc. (OTCQB: GTBP) (Euronext Paris: GTBP.PA) announced today that Dr. Jeffrey Miller , Deputy Director of the Masonic Cancer Center, University of Minnesota will be presenting at the Keystone Symposia: Emerging Cellular Therapies: T...

GT Biopharma, Inc. Issues Letter to Shareholders PR Newswire LOS ANGELES, January 24, 2018 LOS ANGELES , January 24, 2018 /PRNewswire/ -- GT Biopharma Inc. (OTCQB: GTBP) (Euronext Paris: GTBP.PA) today announced that Executive Chairman Anthony Cataldo has issued the following letter to shareholders. Fellow Shareholders, I wanted to take the time to thank you for being a shareholder and for your continuing support as we strive to build GT Biopharma into a leading player in the biotechnology...

GT Biopharma, Inc. Files Application for NASDAQ Capital Market Listing PR Newswire WASHINGTON, December 18, 2017 WASHINGTON , December 18, 2017 /PRNewswire/ -- GT Biopharma Inc. (GTBP) today announced that the Company has filed an application to list its common stock on the NASDAQ Capital Market. GT Biopharma is currently quoted as GTBP: OTCQB on the Over the Counter Market. "We believe that elevating the listing of our common stock to the NASDAQ Capital Market is an important step forward in...